Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02577614 · ClinicalTrials.gov registry record · Phase 1
FEIBA and Use of Blood Products in Cardiac Surgery
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02577614 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 12 participants.
The verdict
NCT02577614, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to evaluate the feasibility of the prophylactic administration of Factor VIII Inhibitor Bypass Activity (FEIBA) at termination of cardiopulmonary bypass (CPB) period. Specifically, the proposed study is designed to demonstrate the potential role of FEIBA administration in reducing the need for allogeneic transfusion to treat refractory coagulopathy in high risk patients.
Interventions
- DRUG Normal Saline
- DRUG FEIBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02577614
The ClinicalTrials.gov registry entry for NCT02577614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT02577614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02577614 about?
NCT02577614 is a clinical study titled "FEIBA and Use of Blood Products in Cardiac Surgery". The purpose of this pilot study is to evaluate the feasibility of the prophylactic administration of Factor VIII Inhibitor Bypass Activity (FEIBA) at termination of cardiopulmonary bypass (CPB) period. Specifically, the proposed study is designed to demonstrate the potential role of FEIBA administra...
What is the current status of trial NCT02577614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-02. Estimated completion is 2020-03.
What interventions are being tested in trial NCT02577614?
The interventions under investigation include: Normal Saline (DRUG), FEIBA (DRUG).
Who is sponsoring clinical trial NCT02577614?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.